Quotient Sciences acquires CDMO Arcinova

By The Science Advisory Board staff writers

February 9, 2021 -- Quotient Sciences has purchased U.K. multiservice contract development and manufacturing organization (CDMO) Arcinova.

For Quotient, the deal expands its service portfolio and will integrate drug substance, drug product, and clinical testing capabilities under one portfolio, according to the firm. Arcinova has 160 employees and provides drug substance, drug product, and bioanalysis services to over 200 pharma and biotech customers around the world, the company said.

Arcinova's minority equity partner BGF, which has backed Arcinova since 2018, will exit the business as part of the deal.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.